Jounce Therapeutics - JNCE Stock Forecast, Price & News

7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Jounce Therapeutics in the last year. There are currently 1 hold rating, 5 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" JNCE shares.
View JNCE analyst ratings or view top-rated stocks.

7 Wall Street analysts have issued 12-month target prices for Jounce Therapeutics' stock. Their JNCE share price forecasts range from $5.00 to $17.00. On average, they anticipate the company's share price to reach $11.00 in the next year. This suggests a possible upside of 308.9% from the stock's current price.
View analysts price targets for JNCE or view top-rated stocks among Wall Street analysts.

Jounce Therapeutics' stock was trading at $8.35 at the beginning of 2022. Since then, JNCE shares have decreased by 67.8% and is now trading at $2.69.
View the best growth stocks for 2022 here.

The company is scheduled to release its next quarterly earnings announcement on Thursday, November 3rd 2022.
View our JNCE earnings forecast.

Jounce Therapeutics, Inc. (NASDAQ:JNCE) announced its earnings results on Thursday, August, 4th. The company reported ($0.65) earnings per share for the quarter, topping the consensus estimate of ($0.68) by $0.03.

45 employees have rated Jounce Therapeutics Chief Executive Officer Richard Murray Ph.D on Glassdoor.com. Richard Murray Ph.D has an approval rating of 97% among the company's employees. This puts Richard Murray Ph.D in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other Jounce Therapeutics investors own include Exelixis (EXEL), Teva Pharmaceutical Industries (TEVA), Bausch Health Companies (BHC), CRISPR Therapeutics (CRSP), Novavax (NVAX), Mylan (MYL), Progenics Pharmaceuticals (PGNX), Adaptimmune Therapeutics (ADAP), Incyte (INCY) and Nektar Therapeutics (NKTR).

(JNCE) raised $76 million in an initial public offering (IPO) on Friday, January 27th 2017. The company issued 5,400,000 shares at a price of $13.00-$15.00 per share. J.P. Morgan and Cowen and Company served as the underwriters for the IPO and Wells Fargo Securities and Baird were co-managers.

Jounce Therapeutics trades on the NASDAQ under the ticker symbol "JNCE."

Jounce Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Cowen AND Company LLC (5.50%), Citadel Advisors LLC (3.28%), Assenagon Asset Management S.A. (2.65%), FMR LLC (2.45%), State Street Corp (1.27%) and Congress Asset Management Co. MA (1.05%). Insiders that own company stock include Barbara Gayle Duncan, Elizabeth Trehu, Hugh M Cole, John Duncan Higgons, Kimberlee C Drapkin, Richard /Ca/ Murray, Rock Ventures Ii LP Third and Rock Ventures Iii LP Third.
View institutional ownership trends.

Shares of JNCE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of JNCE stock can currently be purchased for approximately $2.69.

Jounce Therapeutics (NASDAQ:JNCE) has a market capitalization of $139.06 million and generates $26.91 million in revenue each year. The company earns $-90,870,000.00 in net income (profit) each year or ($2.55) on an earnings per share basis.

The company employs 137 workers across the globe.

Jounce Therapeutics' mailing address is 780 MEMORIAL DRIVE, CAMBRIDGE MA, 02139. The official website for the company is www.jouncetx.com. The company can be reached via phone at (857) 259-3840 or via email at mdeon@jouncetx.com.